SUMMARY In 198 patients with acute myocardial infarction serial measurements of plasma creatine kinase isoenzyme MB (CK MB) were performed at four hour intervals. In every patient, maximal CK MB activity (peak activity) was compared with calculated total release per litre plasma. In 28 patients (group 1) sufficient plasma samples were available for calculation of the apparent first order inactivation constant kd. Mean apparent kd in group 1 patients was 0O085±0*018 h-1 (mean±+SD).
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Total release in group 1 was calculated with individual apparent kd values (Q) and with the mean kd value (Q*). In the remaining 170 patients (group 2), Q* only was calculated. A linear relation between peak activity P and total release (both Q and Q*) was found, extending over the whole range of CK MB peak activities that are routinely observed (4-216 U/1). It was immaterial whether a one or a two compartment model was used: both yielded a close linear relation. Though the mean ratio between Q* and peak activity depends on the value of kd chosen for calculation of total release (the ratio increasing with increasing kd), linearity between peak activity and Q* was found for any value of kd up to 0-4 h-.
In group 1, shapes of calculated CK MB release curves Q*(t), expressed relative to maximal release Q(40), were sufficiently similar so as to be superimposable; the section of the release curves extending from 12 hours before until two hours after peak time could be tentatively described by a linear time course with a slope of 4*2±+05% per hour (mean± SD).
We conclude that peak activity of CK MB is a reliable estimate of cumulative CK MB release and may be clinically more practicable than calculation of Q(40). Both the similarity and the large apparently linear section of the calculated enzyme release curves possibly permit early prediction of Q(40), with acceptable precision.
An enzymatic estimation of the amount of necrotic tissue in myocardial infarction should ideally: (1) be available at an early stage after the onset of ischaemic damage to the tissue, (2) be specific for myocardial tissue, and (3) be obtained easily and reliably. The CK MB isoenzyme meets these criteria reasonably well and is therefore routinely used in our department.
From a theoretical point of view the best enzymatic estimate of infarct size is obtained from complete plasma enzyme activity curves, consisting of many data points of serially obtained blood samples. Both one and two compartment models may be used for calculations,' 2depending on the circulatory variables of the partkular enzyme used.3 4 It is necessary to Accepted for publication 11 January 1983 continue blood sampling well beyond the time of maximal plasma enzyme activity in order to determine the rate constant of the clearing process for individual patients.3 4 Good agreement has been shown between CK MB infarct size estimations obtained in this way and histological infarct size determinations at necropsy. 5 7 Since it is of practical clinical importance to obtain an estimate of infarct size as early as possible, the question is legitimate whether an accurate prediction can be made before the enzyme activity curve is completed. There are two obvious candidates for a similar estimate. The simplest and most frequently adopted procedure is to sample until the peak of the activity curve has been reached, and use the peak value as an estimate of total tissue damage. Published reports indicate that this may be a feasible approach. [8] [9] [10] [11] For CK MB, peak activity is reached about 20 Blood samples were drawn in evacuated heparinised tubes and immediately centrifuged twice. After addition of a final concentration of 10 mmol mercaptoethanol the plasma was stored at -20°C until determination (usually within 12 hours). CK isoenzyme assay and separation were performed as described previously. 'I For calculation of total CK MB release per litre plasma two mathematical models were applied: (a) the one compartment model, described by Q(t)=Ci(t)+kd$ Ci(t)dt (1) t=O Fiolet, ter Welle, van Capelle, Lie in which Q(t) is the total activity of CK MB released per litre plasma at time t, Ci(t) is plasma CK MB activity observed at time t, and kd is the apparent first order inactivation constant; and (b) the two compartment model, described by Q(t)=Cj(t)+kd X C(t)dt+Ce(t) (2) t=0 in which the additional term Ce(t) allows for the CK MB activity in the extravascular space. Ce(t) is given by tI Differences between means were tested by Student's t test. Differences between standard deviations were tested using the F test. Confidence intervals for correlation coefficients were calculated with Fisher's z-transform.
Results

TOTAL CK MB RELEASE AND MAXIMAL ACTIVITY
In group 1, individual values for the inactivation constants were estimated from semilog plots of at least five data points in the declining limb of the CK MB activity curves. The values of kd found were 0-085+0-018 per hour (mean+ SD).
For group 1, total enzyme release was calculated with the one compartment model at t=40 hours with both the mean kd (Q*(40)) and with individual kd (Q(40)). Table 1 . No statistically significant differences existed -in peak activity and peak time, but kd values were significantly different (p<0.05) between the two subgroups. Fig. 3 shows the correlation between peak activity and Q*(t) in 170 patients of group 2. Q*(t) was calculated, on the average, approximately eight hours after peak time. The mean ratio between Q*(t) and peak activity is 2-05±0-23 (mean±SD), somewhat lower than that seen in Fig. 1 . The difference is not statistically significant.
In group 1 we also calculated Q(40), using the two compartment model. As in the one compartment model, the relation between peak activity and Q(40) is linear (not shown), r=0'99. The mean ratio of Q(40) to peak activity in this case is 2-33±0-26 (mean±SD). Table 1 Characteristics ofplasma CK MB cwves in patients with high and low ratios ofreleaselpeak That this is higher than the ratio found in the one compartment model is because of the term for the extravascular CK MB contribution to Q(40) in formula 2. Fig. 4 shows the effect of using a high kd value on the ratio of Q(t) to peak activity as compared with using the apparent individual kd value in an individual patient. Using the high kd value in calculating Q(t) has two effects: firstly, the ratio Q(40) to peak activity increases, and, secondly, enzyme release appears to Fig. 4 Time course of ratio between Q(t) and peak activity in an individual patient. O O time course of intravascular activity of CK MB C(tt); * * time course of calculated extravascular activity C/t); A -A ratio between Q(t) and peak actizity, kd =0-077h-1; x x ratio between Q*(t) and peak actitity, kd =0-250h-1. Q and Q* are calculated by applying the two compartment model. continue for a much longer period of time. In this particular patient, enzyme release at kd=0-077 seems complete after 25 hours, whereas for kd=0-250 enzyme release continues until approximately 50 hours.
When high kd values are used for Q*(40) calculation, linearity between peak activity and Q*(40) is maintained. The ratio of Q*(40) to peak activity, however, increases with increasing kd. This is illustrated in Fig. 5 . For all kd values, essentially constant ratios are found, with similar coefficients of variation.
PREDICTABILITY OF TOTAL CK MB RELEASE
As illustrated above, measured maximal CK MB activity is a reasonably good predictor of total CK MB release. Acceptable prediction may well be possible earlier than time of peak activity, since neither peak activity itself nor the time of its occurrence has a specific significance in the release curve.
Normalised release curves of the patients in group 1 are shown on a relative time scale in Fig. 6 . Zero time is arbitrarily set at 500/o of enzyme release, and all Q*(t) values of the individual patients are calculated relative to Q* at t=40 hours. Q*(t) was calculated using the two compartment model with kd=0-250. For patients in group 1, the mean peak time relative to the time of onset of complaints was 218+3-0 hours (mean± SD). Mean peak time relative to arbitrary zero time (time at which Q(t)=50%) was 1*7+1*4 hours (mean±+SD). This SD is significantly smaller (p<0*005) than the one referred to first.
Discussion
In previous studies, cumulative enzyme release was related to infarct size, mainly by using curves obtained from serial CK measurements.' 2 14-19 Infarct size estimates from these curves have shown a 6 Normalised release curves of CK MB in group I patients. Every individual release curve Q*(t) is normalised relative to the individual Q at t=40h. The individual release curves are plotted on a relative time scale, which is arbitrarily set to zero at Q*=50%. Mean time ofmaximal plasma CK MB activity is indicated by the arrow. Q*(t) is calculated by applying the two compartment model, with kd =0-250h.-1. relation to mortality and left ventricular performance.8 11 14 16 17 Though it has been stressed that estimates of infarct size from cumulated CK release should be interpreted with caution,'9 good correlation with postmortem infarct size determinations was shown. 19 Because of the high cardiospecificity of the CK MB isoenzyme, its cumulated release after myocardial infarction should, theoretically, give more accurate estimates of infarct size, especially under circumstances where less specific enzymes could contribute activity from non-cardiac origin. 20 In patients with uncomplicated acute myocardial infarction, similar shapes of CK MB curves were found, irrespective of whether or not these patients received intramuscular injections. The shapes of their total CK curves, however, differed.20 A highly significant correlation was reported recently between CK MB estimated infarct size and postmortem determinations.6 7 In addition, correlation was found with radionuclide estimates of infarct size. 2' This study shows that measured maximal plasma CK MB activity in patients with acute myocardial infarction is linearly correlated with CK MB release per litre plasma, accumulated during 40 hours after the onset of symptoms (Q(40)). This linear relation holds over the whole range of maximal CK MB activities found in patients with acute myocardial infarction. Thus, an average ratio between measured maximal activity and calculated cumulative release exists. The value of this ratio is scarcely influenced by the kind of model used in the calculations. This is in agreement with earlier findings, especially for enzymes with relatively high kd values.34
Apparently, the value of the ratio between Q(40) and maximal activity is highly dependent on the value of kd used in calculating Q(40). On the basis of the fundamental similarity of release kinetics for different enzymes from infarcting myocardium, it has been argued that true kd values for CK MB are considerably larger than those determined from the apparent monoexponential declining limb of the CK MB curve and, in fact, cannot be determined in that manner. 3 4 This is also in agreement with high kd values for CK and its isoenzymes found in experimental studies involving intravenous injection of the isoenzymes in the dog.22 23 For CK MB injected into baboons, however, a much lower value was reported. 24 The consequence of a much higher kd value is that enzyme release may continue beyond 40 hours after the onset of complaints (cf Fig. 4) Several other factors contribute to the interindividual variation in the Q(40)/peak ratio. Firstly, the 5% coefficient of variation of the CK MB assay'3 contributes fully to the variability of the peak activity and partially to the variability of Q(40). Secondly, the underestimation of the true maximal activity by measured maximal activity is an additional source of variation. For sampling intervals of four hours, it was recently found that measured maximal activity of CK deviates from true peak activity by less than 6% on the average; CK values remained at greater than 90% of peak for a mean of 7 6 hours. " I Thirdly, accuracy and precision of the calculation of Q(40) depend on the sampling frequency. For CK MB it has been shown that cumulative release calculated for sampling intervals of one hour correlated significantly with that calculated for eight hour sampling intervals (r=0.997, SEE=6%5). Furthermore, for our calculations it was assumed that in all patients the first rise in plasma CK MB activity occurred four hours after the onset of complaints. This first activity increase, however, may have occurred earlier, especially in patients with larger infarctions. Moreover, there is an intrinsic uncertainty in the assumed time of onset Qf pomplaints. A fourth factor which may contribute to the observed variation in the ratio Q(40)/peak is the possible occurrence of small infarct extension or expansion. '8 25 This cannot be ruled out because selection of patients for this study was based only on the clinical diagnosis of acute myocardial infarction upon admission, and on the criteria for suitable CK MB plasma activity curves, mentioned in the method section. Clear, double-peaked plasma activity curves, however, were not observed. Alternatively, statistically significant deviation from the mean of the Q(40)/peak value for a particular patient may be used to establish or confirm the diagnosis of reinfarction.
Our results indicate that CK MB peak activity is a reliable estimate of ultimate total enzyme release and, therefore, that this release is predictable. Prediction Infarct size estimation from serial CK MB determinations: peak activity and predictability occurs at peak time, which is considerably earlier than the time at which enzyme release is completed. There is no reason why predictions could not be made even earlier, since peak time has no special significance in the time course of enzyme release. Successful prediction of infarct size was reported from data points in the first seven hours after initial CK rise in patients with acute myocardial infarction. 5 Other attempts at prediction have been disappointing thus far; variable and unacceptable inaccuracy was shown, especially early in the time course."I 12 This inaccuracy, however, may be the result of the predictive procedure used, which involves curve-fitting to successively fewer data points. This procedure may introduce considerable uncertainties in the coefficients of the "fitting" equation, especially if only a few early data points are available.
The results described in Fig. 6 indicate a possibly more promising approach. Superimposed release curves appear similar and linear for a considerable period of time. Enzyme release curves of individual patients show no appreciable difference in slope of the linear sections. The mean slope gives the fraction of total enzyme released per unit time. Whether or not the linear section of the release curve (Q*(t)) has been reached can be evaluated from CK MB activity in multiple, early, densely-spaced plasma samples. In this way, the difficulties encountered in determining the exact time of onset of complaints are avoided. Subsequently, ultimate Q*(40) may be predicted from both the early Q*(t) values in the linear section of the release curve and the above-mentioned mean slope value. This approach may eliminate possible errors caused by curve fitting.
The feasibility and predictive precision of this procedure are presently under investigation. A predictive imprecision of about 10% (coefficient of variation of individual slopes) seems attainable, perhaps even less if precision of the CK MB assay, especially at low activities, can be improved. Clinical interventions may reduce infarct size by about 200/o.2 26 Such interventions may be evaluated in the individual patient if a predictive imprecision of less than 10% can be achieved.
